The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
Clinical trial NCT07376174 · RECRUITING
Trial details
- NCT number
- NCT07376174
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-01-10
- Primary completion
- 2026-06-10
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.